 |
|
|
|||||
Sunday night’s Super Bowl and Bad Bunny fell short of setting records for most watched U.S. broadcast and halftime show.Seattle’s 29-13 victory over New England averaged 124.9 million viewers on NBC, Peacock, Telemundo, NBC Sports Digital, and NFL+, according to Nielsen’s Big Data + Panel rating system.That fell short of the 127.7 million U.S. viewers that tuned in for Philadelphia’s 40-22 victory over Kansas City last year on Fox.However, Super Bowl 60 is the most-watched program in NBC history. The network is celebrating its 100th anniversary this year.Bad Bunny’s halftime show averaged 128.2 million viewers from 8:15-8:30 p.m. Eastern. That would make it the fourth-most watched halftime behind Kendrick Lamar (133.5 million, 2025), Michael Jackson (133.4 million, 1993) and Usher (129.3 million, 2024). Peak audience sets U.S. record The audience for the game peaked at 137.8 million viewers during the second quarter (7:45-8 p.m. Eastern), which is a record. That surpassed the previous mark of 137.7 million during the second quarter of last year’s Super Bowl.This year’s audience ended a streak where the last four Super Bowls had experienced audience increases. It is the fifth straight year the game has averaged over 100 million viewers.After three straight years of Super Bowls that came down to the final minute, the last two have lacked excitement.Sunday’s game was the second in Super Bowl history in which a touchdown had not been scored in the first three quarters. Seattle was up 12-0 going into the final 15 minutes.Last year’s game was decided in the first half as Philadelphia built a 24-0 lead en route to a 40-22 victory. Bad Bunny versus Kid Rock The Turning Point USA halftime show featuring Kid Rock peaked at 5 million at one point on YouTube.Nielsen did not measure any of the YouTube live stream viewership. Of the linear networks that carried it, the only one Nielsen measures is broadcast network Charge! Full Nielsen ratings for the prior week will be released on Wednesday.According to YouTube figures though, there have been 21,208,583 views of the alternate halftime show through Tuesday night, according to the conservative organization’s page. Bad Bunny’s show has already had 61,311,972 views. Halftime show on social media Total social media consumption of Bad Bunny’s halftime show set a record of 4 billion views after the first 24 hours, according to the NFL and Ripple Analytics. That is a 137% increase over last year.The social media figures include fans, owned platforms, broadcast partners and influencers.The NFL said over 55% of all social views came from international markets.Full global viewership for the halftime show is expected to be available early next week. Spanish audience record Telemundo averaged 3.3 million viewers, making it the most-watched Super Bowl Spanish-language broadcast in the United States. The Super Bowl has been televised in Spanish in the U.S. since 2014.The audience peaked during the halftime show, averaging 4.8 million viewersalso making it the most-watched Super Bowl halftime in Spanish-language history. Olympics benefit from Super Bowl NBC’s “Primetime in Milan” Olympic show, which featured the women’s downhill and team figure skating events, averaged 42 million viewers, the network’s largest Winter Olympics audience since Day 2 of the 2014 Sochi Games.It also was a 73% increase from the Olympics show after Super Bowl 56 (24.3 million).“The Super Bowl and the NFL once again delivered a blockbuster audience across the NBC broadcast network, Peacock, and Telemundo, and provided an unprecedented lead-in to our Primetime in Milan coverage,” NBC Sports President Rick Cordella said in a statement. “The Super Bowl and the Olympics are the two most powerful events in the world, and we salute our talented production, tech, and announce teams who delivered best-in-class presentations for our viewers, stations and partners.” Other NFL figures The NFL playoffs averaged 37 million viewers the first three weekends, up 5% from last year and the second-most watched in the last 10 years.That followed a regular season that averaged 18.7 million, the second-highest since audience averages began being kept in 1988. It was a 10% increase from last season. AP NFL: https://apnews.com/hub/nfl Joe Reedy, AP Sports Writer
Category:
E-Commerce
For the past few weeks, political ads attacking Alex Bores have been running in New Yorks 12th Congressional District. The ads are funded by a pro-AI political action committee that supports the expansion of artificial intelligence, yet they aim to weaken Boress candidacy by tying him to his past work in tech. They accuse Bores, who has recently called for abolishing Immigration and Customs Enforcement (ICE), of hypocrisy because he previously worked at Palantir, a data analytics company whose contracts with ICE have made it a frequent target of activists. The ads allege that Bores made hundreds of thousands of dollars building and selling technology for the agency. Now hes running from his past, while ICE is in our communities, one ad warns. ICE is powered by Boress tech . . . he should never, ever be in Congress. Inside Palantir, the ads are starting to irk some employees. Two current employees and three former employees tell Fast Company that they view the campaign as opportunistic. Some believe the ads misrepresent Boress record at the company. Others say Palantirs approach to its work with ICE has changed since Bores left the company many years ago. Several employees said they see the ads as less about immigration enforcement and more about politics within the tech industry. They point to the PAC funding the campaign, Leading the Future, as evidence that the effort is primarily about countering Boress support for AI regulation. That view is shared by one former Biden administration staffer who, speaking on condition of anonymity, emphasized that the ad campaign was almost certainly a response to Boress role as a lead sponsor of an AI safety bill in New York. If Boress campaign is one that would restrict the tech industrys growth, and his base is one that is already primed to be critical of Palantir, people (like me!) who watch this ad wouldnt suspect that its people with significant interests in Palantir and the broader industry that are funding the ads, too, one former employee tells Fast Company in a message. Bores, a member of the New York State Assembly who successfully pushed for AI regulation at the state level, is currently running for the Democratic nomination for New Yorks 12th Congressional District. The district represents the very liberal and very wealthy neighborhoods of Manhattans Upper West and Upper East Sides, meaning the winner of the Democratic primary is all but guaranteed to win the general election. Bores has leaned into his tech background on the campaign trail. He says he is proud of his work at Palantir but left the company seven years ago in response to its work for ICE, a project he says he never worked on or participated in. Since then, however, he has been the subject of an extended ad campaign branding him an expert in hypocrisy and alleging that he profited from Palantirs work with the Department of Homeland Security. The ads seek to capitalize on widespread anger over ICE, particularly following a massive escalation of raids and deportations and the killing of two American citizens. Boress campaign has since sent Leading the Future a cease-and-desist, Semafor recently reported. Joe Lonsdales role in the anti-Bores effort The ads are being released by Think Big, a group that describes itself as supporting pro-AI Democratic leaders. Think Big is funded by the Super PAC Leading the Future, according to Federal Election Commission documents. Leading the Futures founding supporters, according to its own press release, include Palantir co-founder Joe Lonsdale, OpenAI co-founder Greg Brockman, venture capitalists Marc Andreessen and Ben Horowitz, and the AI company Perplexity. Multiple donors associated with the groupsuch as Lonsdale and Andreessenhave also been major contributors to Republican candidates and causes. Campaign finance records show that Lonsdale Enterprises is the only donor, aside from Leading the Future itself, listed on filings associated with American Mission, a separate PAC affiliated with the same network. (Super PACs can raise and spend unlimited sums but are prohibited from donating directly to candidates. Traditional PACs face strict contribution limits but are allowed to donate to campaigns, leading many political networks to operate both.) The co-founder of Palantir started a Super PAC that is lying to New Yorkers about my work and the fact that I quit seven years ago over the ICE contract they continue to profit off of to this day, Bores tells Fast Company. The real issue, Bores argues, is his work on AI regulation. He co-sponsored a New York state law known as the Raise Act, which was signed last year by Governor Kathy Hochul and imposes safety requirements on frontier AI developers. He has said he plans to pursue similar legislation in Congress. John Vlasto, a leader at Leading the Future, said in an emailed statement: Leading the Future will aggressively oppose policymakers and candidates in states across the country who play political games with the future of American leadership and jeopardize American workers, families, and communities ability to benefit from AI innovation and growth. Palantir did not respond to Fast Companys request for comment. Now Palantir employees are grappling with the growing public scrutiny of the companys work with ICE and the way that criticism is being deployed politically. One current employee said Bores was always upfront internally about his background and found it jarring that a PAC backed by tech funders would attack someone for having worked in the technology industry. Another current employee said the ads and campaign materials highlighting Palantirs ICE contracts feel disingenuous, adding that the work remains controversial inside the company. (Indeed, Wired reported on Tuesday that Palantir employees have spent weeks pressing company leadership for answers about its work with ICE, prompting CEO Alex Karp to address the issue in a prerecorded internal video.) That tension has fueled anger among some employees that Lonsdale, a Palantir co-founder, appears to be amplifying criticism of the company based on its federal contracts. Theres even a Slack thread where people have flagged the ads and other campaign materials theyve received, one employee tells Fast Company. Nothing says principled stance like a founder denouncing their own companys employees for their own companys choices, Varoon Mathur, who worked on AI at the Biden White House, tells Fast Company. Another former Biden administration official similarly emphasized that the campaign was almost certainly because Bores sponsored AI safety legislation in New York. Controversy over ICE and Palantir The ads targeting Bores come amid growing criticism of Palantirs work with ICE. The company has worked with the Department of Homeland Security for more than a decade, but its current relationship with the federal government primarily centers on ICE. That work includes a product called ImmigrationOS, which assists the agency with deportation operations, as well as support for an ICE tip line that was recently disclosed in the agencys AI inventory. Work on the tip line began years ago but was shifted to Palantir during the second Trump administration, a former DHS employee tells Fast Company. (Palantir has also faced criticism for its contracts with the Israeli military during the war in Gaza.) The companys growing political baggage has made it a liability for some elected officials. In New York City, finance officials are pressing for an inquiry into the citys pension fund, which is invested in Palantir. In Colorado, Sen. John Hickenlooper and Rep. Jason Crow announced this week that they would offset campaign contributions from current and former Palantir employees by donating to immigrant rights groups. In Florida, far-right candidate James Fishback has called for banning the company from the state. For Bores, that scrutiny has extended to his own tenure at Palantir. He previously told Fast Company that he left the company when, or soon after, Palantir renewed an ICE contract that expanded the scope of its work with the Department of Homeland Security. However, City & State reported last month that Bores remained at Palantir after controversy over the ICE contract first emerged. (Boress spokesperson told the outlet that he left before the contract was renewed, and he believed the contracts renewal was likely.) Two Palantir employees who spoke to Fast Company said they had no reason to believe Bores worked on the ICE contract specifically, and one said they remembered him opposing the companys work with ICE internally. Some Palantir employees have also donated to his campaign, Bores has said. Current and former employees describe a company long divided over its government contracts, particularly those tied to immigration enforcement. One former employee said the ads were frustrating but predictable, given Palantirs history of pursuing government work across administrations. Another said they left the company after its approach to ICE shifted away from earlier guardrails, adding that the advertisements felt like retribution. A third former employee recalled internal conversations that look pretty different from at least what Im seeing publicly about Palantir now. Bores, for his part, has tried to turn the PACs focus on him into a political asset, framing it as validation of his push for AI regulation. Judge me by my enemies, he wrote in a recent tweet, referring directly to Lonsdale.
Category:
E-Commerce
A canine health startup called Loyal has now raised more than $250 million to develop drugs that could help dogsand perhaps one day humanslive longer, healthier lives. The company on February 11 announced it had raised $100 million in Series C funding as it pursues FDA approval of LOY-002, a beef-flavored daily prescription pill designed to extend the healthy lifespan of senior dogs. The drug mimics some of the effects of a calorie-restricted diet in addressing age-related metabolic issues without requiring pet owners to cut their dogs food supply or curbing canine appetites. People do not want their dogs to not have food motivation, because that’s how you train dogs, says Loyal founder and CEO Celine Halioua. How we domesticated dogs was sharing meals with them; losing that can actually really impact the dog-human bond. But, of course, people do want to share that bond longer than the typical canine lifespan allows. Halioua started Loyal in late 2019 after a stint as chief of staff at The Longevity Fund, a lifespan-focused investment fund founded by Laura Deming and an early backer of Loyal. She says she realized that dog longevity drugs could one day lead to similar treatments for humans, since the species are similar in many ways, and are easier to test, since dogs short lives mean tests of lifespan extension can be run in a shorter amount of time. And as a dog lovera recent interview with Fast Company also included Haliouas freshly adopted Rottweiler, Wilmashe also saw the potential market among owners and pets. Celine Halioua [Photo: Loyal] It felt like a really tractable way to work on a problem that everyone cares about, which is having too little time with the dogs you love, she says. LOY-002 is one of three canine longevity medications under development by the company, and Halioua says shes hoping Loyal can submit the final requirement for the FDAs expanded conditional approval of the drug this year. That would likely start a roughly six-month review process of what would be the first FDA-approved lifespan extension drug for any species. And its progress comes as interest rises overall in the potential of developing medical treatments that can help humans as well experience longer and healthier lives. When I started pitching The Longevity Fund in 2013, it was a niche concept and people laughed me out of their offices, Deming tells Fast Company in an email. Now it’s a legitimate category of investment. Loyals Series C backers include Age1, a new longevity-focused VC firm cofounded by Deming and Alex Colville, as well as Baillie Gifford and other existing investors in the company, which had previously raised more than $150 million in investments. LOY-002 is Loyal’s lead drug program, developed to extend lifespan in senior dogs. It is currently in clinical trials and is advancing through the regulatory pathway towards FDA Expanded Conditional Approval (XCA) [Photo: Loyal] Aging is something that really affects everybodyevery human and every dog on the planet experiences aging, Colville says. And I think that’s something that’s really unique about it as an opportunity and a space to work in. Already, LOY-002 has met two of three milestones for FDA approval, known as the target animal safety and reasonable expectation of effectiveness sections of its conditional approval application. The final milestone involves demonstrating that the drug can be consistently manufactured at scale, Halioua says. The drug will likely be labeled for use by dogs at least 10 years old weighing at least 14 pounds, she says. Dosing, and thus costs, will depend on animal size, but Halioua says shes optimistic the average dog will be able to take the drug for less than $100 per month. The company announced last July that it had completed enrolling dogs in a study it calls STAY, designed to test the effectiveness of LOY-002, which Halioua says is the largest-ever animal health clinical trial. Loyal has enrolled roughly 1,300 dogs in the study through 72 veterinary clinics, and Halioua says shes hoping theyll find that the drug confers at least one healthy to participants. Loyal also has two other dog drugs, a vet-administered injection called LOY-001 and a daily pill called LOY-003, in the works. Though Halioua says the company hasnt publicized the exact biological mechanisms beyond the drugs, she says would look to extend lifespans of larger dogs by targeting a growth hormone thats correlated with a shorter life, with big dogs usually living a shorter time than their smaller counterparts. [Photo: Loyal] Once the dog is fully grown, you can then reduce the levels of growth hormone to hopefully extend their healthy lifespan and kind of compensate for the historical genetic issue that we gave them when we selectively bred for size, says Halioua. If all goes well, those drugs could launch a year or two after LOY-002, she says. And if Loyals drugs prove helpful to dogs, they could one day lead to similar treatments for humans. If we’re able to do something helpful for dogs, I think we’re going to learn a lot about how to do something helpful for humans, too, says Halioua.
Category:
E-Commerce
All news |
||||||||||||||||||
|
||||||||||||||||||